Management of resistance to EGFR TKI–Targeted therapy of lung cancer: Lessons in monitoring cancer evolution

Arkadiusz Z. Dudek

Management of resistance to EGFR TKI–Targeted therapy of lung cancer: Lessons in monitoring cancer evolution

Arkadiusz Z. Dudek

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

Abstract

Cancer cells undergo accelerated evolutionary changes; thus, under the pressure of novel generations of EGFR TKIs, we should expect to see new mechanisms of resistance.

Original language	English (US)
Journal	ONCOLOGY (United States)
Volume	30
Issue number	7
State	Published - Jul 15 2016

Access

Fingerprint Dive into the research topics of 'Management of resistance to EGFR TKI–Targeted therapy of lung cancer: Lessons in monitoring cancer evolution'. Together they form a unique fingerprint.

Cite this

@article{6b2f1d0652df42c5b0f57e128e74bf6a,

title = "Management of resistance to EGFR TKI–Targeted therapy of lung cancer: Lessons in monitoring cancer evolution",

abstract = "Cancer cells undergo accelerated evolutionary changes; thus, under the pressure of novel generations of EGFR TKIs, we should expect to see new mechanisms of resistance.",

author = "Dudek, {Arkadiusz Z.}",

year = "2016",

month = jul,

day = "15",

language = "English (US)",

volume = "30",

journal = "Oncology",

issn = "0890-9091",

publisher = "UBM Medica Healthcare Publications",

number = "7",

}

TY - JOUR

T1 - Management of resistance to EGFR TKI–Targeted therapy of lung cancer

T2 - Lessons in monitoring cancer evolution

AU - Dudek, Arkadiusz Z.

PY - 2016/7/15

Y1 - 2016/7/15

N2 - Cancer cells undergo accelerated evolutionary changes; thus, under the pressure of novel generations of EGFR TKIs, we should expect to see new mechanisms of resistance.

AB - Cancer cells undergo accelerated evolutionary changes; thus, under the pressure of novel generations of EGFR TKIs, we should expect to see new mechanisms of resistance.

UR - http://www.scopus.com/inward/record.url?scp=84984832153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984832153&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84984832153

VL - 30

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 7

ER -